The idea that ecopipam “fixes” stuttering is, at best, premature and overblown. All solid evidence for fluency improvement is anecdotal or from tiny, uncontrolled studies. The only rigorous trial has been completed without fanfare, implying it likely failed to show a benefit (no efficacy data have been released). Experts also warn that the standard subjective fluency scales are flawed, meaning small or placebo-like changes could have been interpreted as “effect” in the uncontrolled setting. In light of this, continuing to champion ecopipam as a stuttering solution borders on wishful thinking. Fluency researchers recall that prior “miracle drugs” (various antipsychotics) showed limited gains at the cost of side effects. Indeed, ecopipam’s tolerability may be better than D₂-blocking drugs, but without clear efficacy, it offers nothing concrete to patients. It is irresponsible to raise hope in 3+ million stutterers without data. As one stuttering expert noted, if ecopipam truly improved speech, the company would be clamoring to publish those results. Instead, they have gone silent – a classic sign of negative or inconclusive findings. Given the null evidence, time and resources may be better spent elsewhere. Stuttering is multifactorial, and there is already ongoing research on neurostimulation and behavioral therapies. Chasing a single dopamine-blocker as a panacea ignores the field’s complexity. In sum, ecopipam’s promise for stuttering has been hyped far beyond the facts. Without robust trial data, calling it a “cure” is misleading at best.